ONC-PluReceptor NK Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ONC-PluReceptor NK Cells, covering 2026-04-20 to 2026-04-20. Get the full timeline:
Most recent: Clinical Trial Update: Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]